SCHEMBL20883565

SCHEMBL20883565

CC(C)c1ccc(N2CCN(C(=O)N3CCCC3)CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 10/20 0.67
▸ ALDH1A1 P00352 6/20 0.67
▸ SMN1; SMN2 Q16637 6/20 0.67
▸ LMNA P02545 3/20 0.67
▸ HTT P42858 2/20 0.67
▸ HPGD P15428 2/20 0.67
▸ MAPT P10636 5/20 0.60
▸ GFER P55789 1/20 0.60
▸ PANK3 Q9H999 4/20 0.56
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ MAPK1 P28482 2/20 0.54
▸ TP53 P04637 2/20 0.54
▸ THRB P10828 1/20 0.54
▸ KDM4E B2RXH2 2/20 0.53
▸ GAA P10253 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ ALOX12 P18054 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14923983 0.88 AKR1C3 (0.70) AKR1C3ALDH1A1LMNAMAPTGAA
SCHEMBL10288811 0.83 PANK3 (0.58) ALDH1A1SMN1; SMN2LMNAHTTHPGD
SCHEMBL10169298 0.83 MAPT (0.71) ALDH1A1SMN1; SMN2LMNAHTTHPGD
SCHEMBL23544884 0.82 PANK3 (0.57) ALDH1A1SMN1; SMN2LMNAHTTMAPT
SCHEMBL22854086 0.82 PANK3 (0.57) AKR1C3ALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL4985735 0.81 AKR1C3 (0.68) AKR1C3ALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL22542072 0.81 AKR1C3 (0.76) AKR1C3ALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL20884954 0.81 AKR1C3 (0.58) AKR1C3ALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL20883570 0.81 PANK3 (0.56) ALDH1A1SMN1; SMN2LMNAHTTMAPT
SCHEMBL23544877 0.81 PANK3 (0.56) ALDH1A1SMN1; SMN2LMNAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10807994-B2 Heterocyclic compounds and uses thereof NUVATION BIO INC. (US) 2020-10-20 — — US disclosed
US-20190106436-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-04-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106436-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF WEE1, WEE2, NME1 AKR1C3 3590/4885ALDH1A1 2869/4885SMN1; SMN2 4343/4885
US-10807994-B2 Heterocyclic compounds and uses thereof WEE1, WEE2, CCNE1 AKR1C3 2214/4885ALDH1A1 1113/4885SMN1; SMN2 4150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback